November 2023
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
This conference focused on the future for the life sciences sector in the UK.
It was an opportunity to examine the Life Sciences Growth package of initiatives launched by the Chancellor earlier this year, and the way forward for supporting life sciences companies to develop and access investment, with the sector identified by the Government as a priority driver of UK economic growth.
Key stakeholders and policymakers examined progress and next steps for the Vaccine Taskforce model approach to tackling health challenges in the UK, following the Life Sciences Vision.
They assessed government investment so far and priorities going forward, including for improving patient access to innovation and collaboration between industry, the NHS, academia and government.
Further sessions looked at key regulatory developments and government plans for implementing recommendations from Professor Dame Angela McLean’s Pro-innovation Regulation of Technologies Review on Life Sciences. Delegates will also discuss priorities for research following Lord O’Shaughnessy’s review on commercial clinical trials in the UK.
We are pleased to have been able to include keynote sessions with: Thomas Lyle, Deputy Director, Office for Life Sciences; Stuart Carroll, Director, Market Access and Policy Affairs, Moderna; and former Member, Vaccines Taskforce; Dr Jennifer Harris, Director of Research and Development Policy, Association of the British Pharmaceutical Industry; and James Roach, Managing Director, Conclusio.
Overall, areas for discussion included:
- Life Sciences Vision: assessing progress so far - identifying focus areas for research and development funding - priorities for channelling investment - next steps for achieving strategic ambitions
- new taskforce approach:
- harnessing lessons from the development of the COVID-19 vaccine - funding and support for collaboration
- next steps for tackling health challenges such as obesity, cancer, mental health and respiratory conditions
- support for sector growth: UK life science start-ups and scale-ups - innovation and manufacturing - creating a business environment that enables the sector to help meet healthcare ambitions
- encouraging collaboration: strengthening cross-industry partnerships and knowledge-sharing - overcoming research funding barriers
- regulation: developing an effective UK framework - ensuring safety - priorities for improving patient outcomes and enabling access to innovative treatments, medicines and medical devices
- UK global positioning: priorities for the future UK-EU relationship - opportunities for increasing the attractiveness of the UK to the wider life sciences industry - establishing UK research leadership
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from DBT; Department for the Economy, NI; DfE; DHSC; DSIT; GO-Science; HM Treasury; IPO; MHRA; OLS; UKHSA; UKSIN; and the Welsh Government.
